Browsing Tag

KP1077

Zevra Therapeutics Presents Full Data Set on the Cardiovascular Safety and…

Eli Pacheco Sep 10, 2023 0

CELEBRATION, Fla., Sept. 09, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced a poster…

Health

Zevra Therapeutics Presents Design of Phase 2 Clinical Trial Investigating KP1077 for…

Eli Pacheco Jun 3, 2023 0

Zevra is a corporate sponsor of the Hypersomnia Foundation and Beyond Sleepy Conference CELEBRATION, Fla., June 03, 2023 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA)…

Health

KemPharm Completes KP1077 Pre-IND Meeting Process with FDA

Eli Pacheco Feb 23, 2022 0

KemPharm Positioned to Submit IND Application for KP1077 for Idiopathic Hypersomnia by Mid-2022 CELEBRATION, Fla., Feb. 23, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a…